David G Daniel

Summary

Publications

  1. ncbi request reprint Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations
    David G Daniel
    United BioSource Corporation, McLean, VA 22106, USA
    J Psychiatr Pract 13:170-7. 2007
  2. ncbi request reprint Recent developments in pharmacotherapy for the acutely psychotic patient
    David G Daniel
    Bioniche Development, Inc, McLean, VA 22106, USA
    J Emerg Nurs 28:S12-20. 2002
  3. ncbi request reprint Tolerability of ziprasidone: an expanding perspective
    David G Daniel
    Bioniche Development, Inc, McLean, Va 22106 6207, USA
    J Clin Psychiatry 64:40-9. 2003
  4. ncbi request reprint The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy
    David G Daniel
    Bioniche Development Inc, McLean, Virginia, USA
    Int Clin Psychopharmacol 19:9-15. 2004
  5. doi request reprint Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor
    David G Daniel
    United BioSource Corporation, McLean, VA, USA
    Clin Schizophr Relat Psychoses 5:87-94. 2011
  6. ncbi request reprint A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, John Umstead Hospital AAU, Butner, NC 27509, USA
    J Psychiatr Res 41:895-905. 2007
  7. ncbi request reprint From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
  8. ncbi request reprint Intramuscular antipsychotics: clinical experience review
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S3-4; quiz S8. 2004
  9. ncbi request reprint Safety of medications used to treat acute agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S19-24. 2004
  10. ncbi request reprint Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Serv 55:290-4. 2004

Detail Information

Publications17

  1. ncbi request reprint Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations
    David G Daniel
    United BioSource Corporation, McLean, VA 22106, USA
    J Psychiatr Pract 13:170-7. 2007
    ..To report efficacy and safety of transitioning patients receiving intramuscular (IM) formulations of aripiprazole or haloperidol to their respective oral formulations...
  2. ncbi request reprint Recent developments in pharmacotherapy for the acutely psychotic patient
    David G Daniel
    Bioniche Development, Inc, McLean, VA 22106, USA
    J Emerg Nurs 28:S12-20. 2002
  3. ncbi request reprint Tolerability of ziprasidone: an expanding perspective
    David G Daniel
    Bioniche Development, Inc, McLean, Va 22106 6207, USA
    J Clin Psychiatry 64:40-9. 2003
    ..This review of pharmacokinetic and clinical trials of ziprasidone versus placebo and active comparators focuses on the safety and tolerability of both the intramuscular and oral formulations...
  4. ncbi request reprint The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy
    David G Daniel
    Bioniche Development Inc, McLean, Virginia, USA
    Int Clin Psychopharmacol 19:9-15. 2004
    ..Ziprasidone i.m. 5,10, and 20 mg qid, given for 3 days were well tolerated. The transition from i.m. to oral ziprasidone was well tolerated with continuing maintenance of symptom control...
  5. doi request reprint Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor
    David G Daniel
    United BioSource Corporation, McLean, VA, USA
    Clin Schizophr Relat Psychoses 5:87-94. 2011
    ..We analyzed the level of agreement achieved among raters of different nationalities using the NSA-16 and the Positive and Negative Syndrome Scale (PANSS) negative subscale and Marder negative factor...
  6. ncbi request reprint A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, John Umstead Hospital AAU, Butner, NC 27509, USA
    J Psychiatr Res 41:895-905. 2007
    ..Aripiprazole 10 mg/day is effective and well tolerated for patients experiencing an acute exacerbation of schizophrenia...
  7. ncbi request reprint From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  8. ncbi request reprint Intramuscular antipsychotics: clinical experience review
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S3-4; quiz S8. 2004
    ..In this imperfect clinical world, it is essential to have treatments that are both safe and effective for patients with a wide variety of causes of agitation...
  9. ncbi request reprint Safety of medications used to treat acute agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S19-24. 2004
  10. ncbi request reprint Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Serv 55:290-4. 2004
    ....
  11. ncbi request reprint Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
    Peter J Weiden
    Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Clin Psychopharmacol 23:595-600. 2003
    ....
  12. ncbi request reprint Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia
    Daniel E Casey
    Mental Illness Research, Education, and Clinical Center, Portland VA Medical Center, OR 97201, USA
    Neuropsychopharmacology 28:182-92. 2003
    ..Further evaluation is warranted to confirm these findings...
  13. ncbi request reprint Updated treatment algorithm
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S25-6. 2004
  14. ncbi request reprint Future directions in research
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S27-9. 2004
  15. ncbi request reprint Novel therapies for treating acute agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S13-8. 2004
  16. ncbi request reprint Standard therapies for acute agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York 14627, USA
    J Emerg Med 27:S9-12; quiz S7. 2004
  17. ncbi request reprint Psychosis in mania: specificity of its role in severity and treatment response
    Alan C Swann
    University of Texas Medical School, Houston 77030, USA
    J Clin Psychiatry 65:825-9. 2004
    ..Psychosis is a prominent characteristic of manic episodes. We investigated relationships between the presence of psychotic features, the severity of the manic syndrome, and syndrome severity's response to treatment...